CBAY - Cymabay Therapeutics Inc Profile, Share Price, Market Analysis, Charts, Fundamentals

Business Description

Cymabay Therapeutics Inc is a biopharmaceutical company founded in 1988 and based in Newark, California. The company focuses on the development of therapies for liver and metabolic diseases.

Cymabay's lead product candidate is seladelpar, a potent and selective partial agonist of the peroxisome proliferator-activated receptor delta (PPARd), which is being developed for the treatment of primary biliary cholangitis (PBC), nonalcoholic steatohepatitis (NASH) and other liver diseases. PPARd is a nuclear receptor that plays a crucial role in regulating lipid and glucose metabolism, inflammation, and fibrosis in the liver.

Seladelpar has been shown to have a strong therapeutic effect in preclinical and clinical studies, demonstrating a reduction in liver injury, fibrosis, inflammation, and improvement in metabolic parameters. Cymabay is currently conducting several clinical trials to evaluate the safety and efficacy of Seladelpar in patients with PBC and NASH.

Besides seladelpar, Cymabay has a diverse pipeline of preclinical and clinical product candidates focusing on liver and metabolic diseases. These include a potent FXR agonist for the treatment of NASH and other liver diseases, an acyl-CoA synthetase inhibitor for the treatment of metabolic diseases, and a GPR139 antagonist for the treatment of schizophrenia and neuroinflammatory disorders.

Cymabay has collaborations with leading academic institutions and pharmaceutical companies to accelerate the development of its product candidates and expand its scientific knowledge. Additionally, the company has a strong intellectual property portfolio with a focus on composition of matter, methods of use, and formulation patents.

Cymabay's strategy is to bring innovative treatments to patients in need, leverage its scientific expertise and collaborations, and build a sustainable, successful biopharmaceutical company.

CymaBay Announces European Medicines Agency Accepts Marketing Authorization Application for Seladelpar for the Treatment of Primary Biliary Cholangitis

Published Mon, Mar 4 2024 1:00 PM UTC

CymaBay Therapeutics Inc (Nasdaq: CBAY) has recently announced that the European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) for Seladelpar, a potential treatment for Primary Biliary Cholangitis (PBC). This comes after the company submitted applications for Seladelpar to the United Kingdom Medicines and Healthcare products Regulator...

CymaBay Therapeutics Rises with Inducement Grants and Public Offering Success

Published Tue, Feb 20 2024 9:05 PM UTC

CymaBay Therapeutics Continues to Make Strides with Inducement Grants and Public Offering
In a recent press release, CymaBay Therapeutics, Inc. announced the grant of inducement awards to three employees on February 16, 2024, in connection with their commencement of employment at the company. This move comes after the company previously granted awards to four employees i...

CymaBay Thrives with $225 Million Public Offering and Inducement Grants for New Employees

Published Mon, Dec 18 2023 9:05 PM UTC

CymaBay Therapeutics, a renowned clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases, recently announced the grant of inducement awards to four employees in accordance with Nasdaq Listing Rule 5635(c)(4). The company approved the grant of non-qualified stock options, allowing the employees to purchase an aggregate of ...

CymaBay Therapeutics Inc. Raises $225 Million in Public Offering: A Boost for Innovative Therapies and Stock Performance.

Published Tue, Sep 12 2023 2:15 AM UTC

CymaBay Therapeutics Inc. Raises $225 Million in Public Offering - Impact on Share Price
As of the writing of this article, CymaBay Therapeutics Inc. (Nasdaq: CBAY) has announced the pricing of its upsized public offering of common stock and pre-funded warrants, which is expected to result in gross proceeds of approximately $225 million for the company. This offering, ai...